Stock·NASDAQ·Healthcare
Replimune Group, Inc. (REPL)
- Market cap
- $1.02B
- Dividend yield
- 0.00%
- Street target
- $19.50median of 8 analysts
- 52-week range
- $1.50 $16.33
The short version
Where REPL stands today, in four lines, and what CleaRank Financial AI makes of it.
REPL at a glance
Replimune Group, Inc. (REPL): Hold, 49/100 on CleaRank's AI score.
- Trend Mixed: the price is above its 200-day but below its 50-day moving average ($9.05 and $13.77).
- Earnings REPL beat estimates in 1 of its last 6 quarters, yet fell the next day after every one of them.
- Insiders Insiders sold $2.6M and made no open-market purchases over the last 18 months.
Figures as of October 17, 2026.
CleaRank Financial AI
Replimune Group, Inc. (REPL) earns a CleaRank rating of Hold and a model score of 49/100.
Analysts lift the score the most, with 7 of 8 rating the stock a buy and a median target 79.6% above the price. Momentum drags hardest: the 14-day RSI of 31.9 is in the bearish zone and the MACD line is negative. The trend is mixed, with the price 21.15% below its 50-day average of $13.77 yet 20.06% above its 200-day average of $9.05. Across the past year, the stock gained 132.55%.
Only on CleaRank
Figures we compute ourselves from REPL's own price, earnings and insider-filing history. Tap one to see it in context.
Price and trading
The chart, today's range and how far the price has moved over each period.
Trend checks
3/4Price above its 50-day average ›
The price of $10.86 is 21.1% below the 50-day simple moving average of $13.77.Price above its 200-day average ›
The price is 20.1% above the 200-day simple moving average of $9.05.50-day average above the 200-day ›
The 50-day average ($13.77) is 52.3% above the 200-day average ($9.05), the arrangement of a rising longer-term trend.In the upper half of its 52-week range ›
The price sits at 63% of its 52-week range, between $1.50 and $16.33.
REPL share price
Pick a period: each tab shows how far REPL has moved over it, to the last close.
Today's trading
Where REPL sits inside today's range and its 52-week range.
Fundamentals
Valuation against the sector, and the revenue and earnings behind it.
Valuation and quality checks
0/1Beat estimates in most recent reports ›
REPL beat the EPS estimate in 1 of its last 6 reports.
Key statistics
The headline figures for REPL.
As of October 17, 2026, REPL trades at $10.86, with a market value of $1.02B and no P/E ratio (its trailing earnings are negative).
What the numbers say
CleaRank Financial AI's reading of REPL's valuation, growth and risks.
Replimune Group, Inc. (REPL) cannot be valued on earnings, since its P/E is not meaningful because the company lost money over the last 12 months. To put the size in context, the company carries a market value of $1.0B, and its trailing earnings are -$3.15 a share.
Profitability is absent at this stage, with a net margin of 0.00% and an operating margin of 0.00%. Return on equity stands at -134.29%, which is below the sector median of 7.3%. Debt-to-equity is 1.06.
Replimune beat expectations in the August 14, 2026 report by 6.49%, posting -$0.72 a share against an estimate of -$0.77. Even so, the stock slid 2.27% in the next session.
REPL has beaten the EPS estimate in 1 of its last 6 reports, but the share price still dropped in the first session after that beat. For the current fiscal year, analysts expect an average EPS of -$3.01, and -$1.82 for the year after.
Day-to-day swings are the main risk to plan around, as REPL has moved 3.27% on an average session. The price is 33.50% below its 52-week high of $16.33. Insiders sold $2.6M of stock over the last 18 months and made no open-market purchases. Insider sales are often planned in advance or made to cover tax on vesting shares, so they are a weaker signal than buying.
REPL against the Healthcare sector
How REPL compares with the median Healthcare stock CleaRank tracks.
Return vs XLV: Since May 6, 2025, REPL has gained 44.8% against a gain of 31.6% for XLV.
Performance against XLV
REPL and the Healthcare sector fund over the same days.
Revenue and earnings
How much REPL sells, and how much of it becomes profit.
Loss-making: REPL lost $314M in FY2026.
Earnings reality check
Did REPL beat what analysts expected, and how did the stock react?
Earnings record: REPL beat the analyst estimate in 1 of the last 6 quarters.
Market reaction: The stock fell in the first session after 1 of those 1 beats, so a beat has not been enough on its own.
| Report | Estimate | Actual | Surprise | First session | 5 sessions |
|---|---|---|---|---|---|
| Aug 14, 2026after close | -$0.77 | -$0.72 | +6.49% | -2.27% | -1.34% |
| Jun 29, 2026after close | -$0.72 | -$0.76 | -5.56% | -1.16% | +2.77% |
| Nov 6, 2025after close | -$0.79 | -$0.90 | -13.92% | -2.24% | +5.65% |
| Aug 7, 2025after close | -$0.80 | -$0.95 | -18.75% | -3.47% | -2.37% |
| May 22, 2025after close | -$0.69 | -$0.82 | -18.84% | -4.68% | +2.51% |
| Feb 12, 2025after close | -$0.72 | -$0.79 | -9.72% | +3.63% | +3.77% |
As of October 17, 2026, REPL has beaten the analyst EPS estimate in 1 of its last 6 reported quarters and fell in the first trading session after it; its latest report, on August 14, 2026, came in 6.49% above the estimate and the stock moved -2.27% in the first session.
The first session is the first full trading day on the news: the report day itself for a report before the open, the next day for one after the close. Surprise is actual EPS against the consensus estimate.
AI analysis and technicals
CleaRank's score and reasoning, the indicators behind it, and what the price moves with.
Momentum checks
1/3RSI not overbought or oversold ›
The 14-day RSI is 31.9, showing bearish momentum without being oversold.RSI above 50 ›
An RSI of 31.9 is below the 50 midpoint, so sellers have had the upper hand over the last 14 days.MACD line above zero ›
The MACD line is negative, so the 12-day average is below the 26-day average.
CleaRank AI analysis of REPL
The score, the reasoning behind it, and what could move the price next.
Replimune Group, Inc. (REPL) is caught between its two moving averages. At $10.86 the stock trades 20.06% above its 200-day average of $9.05 but 21.15% below its 50-day average of $13.77. That 50-day average sits 52.26% above the 200-day, and the price stands at 63% of the way across its 52-week range, which runs from $1.50 up to $16.33.
The recent dip looks smaller once the longer record is in view. Over the past month the price slid 16.20%, yet over three months it climbed 6.16% and over the past year it gained 132.55%. Momentum is weak for now: the 14-day RSI sits at 31.9, in the bearish zone but not yet oversold, and the MACD line is negative.
Analyst upgrade ›
Wedbush upgraded it to Outperform from Neutral on August 7, 2026.
Source: Analyst action, Wedbush, August 7, 2026Analyst upgrade ›
Leerink Partners upgraded it to Outperform from Market Perform on August 4, 2026.
Source: Analyst action, Leerink Partners, August 4, 2026
Earnings beat ›
The August 14, 2026 report beat the EPS estimate by 6.49%, and the share price fell 2.27% in the first session after it.
Source: Earnings report, August 14, 2026
- The two nearest levels matter most: the 20-day EMA at $12.66 sits above the price, and the 200-day SMA at $9.05 sits below it.
- The 14-day RSI reads 31.9, in the bearish zone, with the MACD line negative; readings above 70 or below 30 mark stretched momentum.
- The share price fell 2.27% in the first session after the August 14, 2026 report. REPL has beaten estimates in 1 of the last 6 reports.
The trend is mixed: REPL is above its 200-day average at $9.05 but below its 50-day average at $13.77. A close above the 50-day would turn both signals up, and a close below the 200-day would turn both down. In the meantime the price sits between the 200-day SMA ($9.05) underneath and the 20-day EMA ($12.66) overhead.
The RSI sits in the bearish band, which leans against a quick recovery.
Technical indicators
Momentum and trend for REPL, from its daily closes.
As of October 17, 2026, with REPL at $10.86, its 14-day RSI is 31.9 (showing bearish momentum without being oversold), its 50-day simple moving average is $13.77 and its 200-day is $9.05.
Calculated by CleaRank on daily closes as of October 17, 2026: Wilder's 14-day RSI, 50- and 200-day simple moving averages, MACD line (12, 26).
What REPL moves with
Correlation of daily returns over one year: +1 moves in step, 0 has no link, -1 moves the opposite way.
As of October 17, 2026, REPL's 1-year correlation of daily returns is +0.03 with S&P 500 (SPY), +0.05 with Nasdaq 100 (QQQ), -0.02 with Bitcoin (BTC) and +0.03 with gold (XAU).
What Wall Street expects
The analysts' target range and how their ratings split.
Analysts checks
3/3Most analysts rate it a buy ›
7 of 8 analysts rate it a buy or strong buy, 0 a hold and 1 a sell.Median target above the price ›
The median 12-month target of $19.50 is 79.6% above the price.More buy ratings than three months ago ›
7 of 8 rate it a buy now, against 4 of 8 three months ago.
REPL Wall Street View
12-month price targets
The price, $10.86, sits below every analyst's target.
Ratings
Recent rating actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Aug 26, 2026 | JP Morgan | Maintains | Overweight |
| Aug 7, 2026 | JP Morgan | Maintains | Overweight |
| Aug 7, 2026 | Wedbush | Upgrade | Outperform |
| Aug 4, 2026 | Leerink Partners | Upgrade | Outperform |
| Jul 31, 2026 | Wedbush | Maintains | Neutral |
| Jul 31, 2026 | Cantor Fitzgerald | Upgrade | Overweight |
As of October 17, 2026, 8 Wall Street analysts cover REPL: 7 rate it a buy or strong buy, 0 a hold and 1 a sell or strong sell. Their 12-month price targets range from $14.00 to $24.00, with a median of $19.50, 79.6% above the price of $10.86.
Source: TwelveData analyst consensus. Targets and ratings belong to the analysts, not to CleaRank.
A trade plan, if you want one
Entry, stop and target levels from the moving averages and recent volatility. Educational, not advice.
REPL trade plan
Entry, stop and target levels, sized to your account. Change the bias or the risk and every level updates.
Entry Strategies pick an entry style
Risk management
Profit targets (Based on Conservative Entry)
REPL moves about 3.3% a day on average, so a stop can fill well past its level. Educational levels, not financial advice; the full disclaimer is at the foot of the page.
Risk profile
How much REPL tends to move, against the market and on its own.
The long record
REPL's worst falls and recoveries, what $10,000 became, and which months have been kind to it.
Track record checks
0/4Average daily move under 2% ›
The price has moved 3.27% on an average day (30-day standard deviation of daily returns).Recovered from its worst fall ›
The worst fall was 96.7%, from November 2020 to April 2026; the price is still 79.0% below that peak.Most 1-year holds ended higher ›
46% of 1-year holding periods in the last 8 years ended with a gain.Beat the S&P 500 since the chart begins ›
$10,000 invested in July 2018 is now worth $7,163.59, against $30,885 in the S&P 500 (SPY).
REPL Drawdowns & Recovery
As of October 17, 2026, REPL's worst peak-to-trough fall over the last 8 years with dividends reinvested was -96.7% (November 2020 to April 2026); it is still 79.0% below that peak, and 46% of 1-year holding periods ended with a gain.
From weekly closing values with dividends reinvested. A drawdown is the fall from the highest value reached so far to a later low.
Growth of $10,000
What $10,000 put into REPL in July 2018 is worth now, against the same amount in the S&P 500.
Against the market: REPL trailed the S&P 500 over this period: $7,163.59 against $30,885.
A $10,000 investment in REPL in July 2018 would be worth about $7,164 today with dividends reinvested, compared with about $30,885 for the same investment in the S&P 500 benchmark (also with dividends reinvested).
Seasonal patterns
Which calendar months have been kind to REPL, and which have not.
Strongest month, June: an average of +35.35%, up in 8 of 8 years.
Weakest month, April: an average of -11.64%, up in 3 of 8 years.
This month, October: has averaged +28.26%, up in 6 of 8 years. Past seasonality does not repeat on schedule.
Over the last 9 years, REPL's strongest calendar month has been June (average +35.35%, up in 8 of 8 years) and its weakest April (average -11.64%, up in 3 of 8 years).
Average return for each calendar month over the last 9 years, from weekly closing prices with dividends included.
Long-term scenarios
Thousands of simulated paths from the price history. A range of outcomes, not a forecast.
Monte Carlo projection
Thousands of simulated paths for $10,000 in REPL, from its own past volatility. The shaded area holds 80% of them.
CleaRank's 10-year Monte Carlo simulation projects that a $10,000 investment in REPL today could grow to about $10,844 by 2036 in the base case, with a 90th-percentile outcome near $82,267 and a 10th-percentile outcome around $1,429. Projections are statistical simulations, not guarantees.
REPL Stock Price Prediction: 2030
The same simulation in share prices, year by year.
CleaRank's simulation projects a price near $11.22 for REPL by 2030 in the base case, from $10.86 today (1.0x over 4 years). The 10th-percentile path ends near $3.11. These are outcomes of a Monte Carlo simulation run on REPL's historical return distribution, not price targets, and they assume no dividends are reinvested.
| Year | 10th percentile | Base case | 90th percentile | range base today |
|---|---|---|---|---|
| 2027 | $5.77 | $10.95 | $20.78 | |
| 2028 | $4.46 | $11.04 | $27.32 | |
| 2029 | $3.67 | $11.13 | $33.76 | |
| 2030 | $3.11 | $11.22 | $40.41 | |
| 2031 | $2.70 | $11.31 | $47.39 |
Method: a lognormal simulation of REPL's own volatility and capped historical trend, re-run daily; base case is the median path, the outer columns the 10th and 90th percentiles.
Insider trading
What the people running the company have bought and sold.
REPL insider trading
Shares the company's directors and officers bought and sold, from their own filings.
Month by month
Open-market purchases above the line, sales below.
Insider buying: No insider bought REPL shares on the open market in the last 18 months. Sales are often planned in advance or cover tax on vesting shares, so they say less than purchases would.
As of October 17, 2026, REPL insiders reported 24 open-market sales worth $2.6M and no open-market purchases over the last 18 months; grants and option exercises are not counted.
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| Aug 20, 2026 | Philip Astley-Sparke
Director
|
Grant | 50.0K | - |
| Aug 17, 2026 | Emily Luisa Hill
Chief Financial Officer
|
Sell | 9.3K | $132.2K |
| Aug 10, 2026 | Sushil Patel
Chief Executive Officer
|
Sell | 39.3K | $510.3K |
| Aug 10, 2026 | Emily Luisa Hill
Chief Financial Officer
|
Sell | 11.4K | $148.5K |
| Aug 10, 2026 | Konstantinos Xynos
Officer
|
Sell | 11.4K | $148.5K |
| Aug 10, 2026 | Andrew Schwendenman
Officer
|
Sell | 7.6K | $99.0K |
| Jun 1, 2026 | Christopher Sarchi
Officer
|
Sell | 12.0K | $110.9K |
| May 18, 2026 | Sushil Patel
Chief Executive Officer
|
Sell | 37.3K | $189.6K |
| May 18, 2026 | Philip Astley-Sparke
Director
|
Sell | 17.7K | $89.7K |
| May 18, 2026 | Konstantinos Xynos
Officer
|
Sell | 14.0K | $71.2K |
| May 18, 2026 | Christopher Sarchi
Officer
|
Sell | 8.6K | $43.8K |
| May 18, 2026 | Andrew Schwendenman
Officer
|
Sell | 7.9K | $40.1K |
| May 18, 2026 | Emily Luisa Hill
Chief Financial Officer
|
Sell | 7.8K | $39.7K |
| Apr 2, 2026 | Christopher Sarchi
Officer
|
Sell | 6.5K | $52.1K |
| Apr 1, 2026 | Philip Astley-Sparke
Director
|
Grant | 50.0K | - |
| Apr 1, 2026 | Emily Luisa Hill
Chief Financial Officer
|
Grant | 50.0K | - |
| Apr 1, 2026 | Sushil Patel
Chief Executive Officer
|
Grant | 251.2K | - |
| Apr 1, 2026 | Christopher Sarchi
Officer
|
Grant | 50.0K | - |
| Apr 1, 2026 | Andrew Schwendenman
Officer
|
Grant | 36.7K | - |
| Apr 1, 2026 | Konstantinos Xynos
Officer
|
Grant | 50.0K | - |
| Feb 18, 2026 | Philip Astley-Sparke
Director
|
Grant | 25.0K | - |
| Dec 19, 2025 | Emily Luisa Hill
Chief Financial Officer
|
Grant | 60.0K | - |
| Dec 19, 2025 | Sushil Patel
Chief Executive Officer
|
Grant | 200.0K | - |
| Dec 19, 2025 | Christopher Sarchi
Officer
|
Grant | 35.0K | - |
| Dec 19, 2025 | Andrew Schwendenman
Officer
|
Grant | 10.0K | - |
| Dec 19, 2025 | Konstantinos Xynos
Officer
|
Grant | 60.0K | - |
| Dec 9, 2025 | Kapil Dhingra
Director
|
Sell | 3.2K | $33.0K |
| Dec 9, 2025 | Kapil Dhingra
Director
|
Option | 3.2K | $5.5K |
| Dec 2, 2025 | Sushil Patel
Chief Executive Officer
|
Sell | 10.0K | $111.3K |
| Nov 17, 2025 | Konstantinos Xynos
Officer
|
Sell | 7.2K | $66.0K |
| Nov 17, 2025 | Christopher Sarchi
Officer
|
Sell | 5.2K | $47.4K |
| Aug 15, 2025 | Emily Luisa Hill
Chief Financial Officer
|
Sell | 9.2K | $49.2K |
| May 20, 2025 | Philip Astley-Sparke
Director
|
Sell | 32.3K | $260.2K |
| May 20, 2025 | Sushil Patel
Chief Executive Officer
|
Sell | 25.1K | $202.3K |
| May 20, 2025 | Konstantinos Xynos
Officer
|
Sell | 8.0K | $64.1K |
| May 20, 2025 | Christopher Sarchi
Officer
|
Sell | 3.7K | $30.2K |
| May 20, 2025 | Andrew Schwendenman
Officer
|
Sell | 3.3K | $26.5K |
| May 20, 2025 | Emily Luisa Hill
Chief Financial Officer
|
Sell | 2.5K | $20.4K |
Source: TwelveData, from SEC Form 4 filings
Questions people ask
Answered from the figures on this page, as of October 17, 2026.